×
Home
Archive Submission Guidelines
News Contact
Original article
Crossmark

Vascularization, proliferative activity and the p53 status in glioblastomas

By
Desanka Tasić ,
Desanka Tasić

University of Nis , Niš , Serbia

Irena Dimov ,
Irena Dimov

University of Nis , Niš , Serbia

Miloš Kostov ,
Miloš Kostov

University of Nis , Niš , Serbia

Dragan Dimov
Dragan Dimov

University of Nis , Niš , Serbia

Abstract

Glioblastomas (GBMs) are among the most vascularized human tumors and the presence of microvascular proliferation is one of the diagnostic hallmarks of these malignancies. The aim of the present study was to investigate the extent of vascularization and its relation to proliferative activity and the p53 status in GBMs. Tissue samples from 100 selected primary GBMs were analyzed by immunohistochemistry for the expression of CD34 in vascular endothelial cells and Ki-67 antigen (using the MIB-1 antibody) and p53 in tumor cells. The microvessel density (MVD), a measure of the extent of tumor vascularization, was evaluated in CD34-immunostained sections in three hot spots and presented as the mean for each tumor specimen. We found that the high MVD was more frequent in tumors showing the high MIB-1-labeling index (MIB-1 LI) as compared to those with the low MIB-1 LI, but the difference was not statistically significant. Also, the extent of vascularization did not differ significantly between p53-negative and p53-positive tumors. Both the level of MVD and the proportion of GBMs with low versus high MVD did not differ significantly in relation to the expression levels of p53 (low vs. high or overexpression). No association was found between MVD and tumor cell MIB-1 LI and the p53 status in primary GBMs. These data suggest that the effect of p53 on primary GBM vascularization failed to detect possibly due to the influence of certain factors, including the presence of other or additional molecular alterations in the tumor cells and the hypoxic microenvironment of tumors. They also support the hypothesis that the effect of p53 on angiogenesis may be tumor-type specific.

References

1.
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology. 2017;19(suppl_5):v1–88.
2.
Alexander BM, Cloughesy TF. Adult Glioblastoma. Journal of Clinical Oncology. 2017;35(21):2402–9.
3.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009;10(5):459–66.
4.
Machein MR, Plate KH. Role of VEGF in Developmental Angiogenesis and in Tumor Angiogenesis in the Brain. Cancer Treatment and Research. 2004. p. 191–218.
5.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007;114(5):547–547.

Citation

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.